Recombinant Rat CD32b/FCGR2B Protein (His Tag)(Active) | PKSR030402

Recombinant Rat CD32b/FCGR2B Protein (His Tag)(Active) | PKSR030402 | Gentaur US, UK & Europe Disrtribition

Synonyms: FCRII;Fcgr2

Active Protein: Active protein

Activity: A DNA sequence encoding the rat FCGR2B (Q63203-1) extracellular domain (Met 1-Pro 212) was expressed, fused with a polyhistidine tag at the C-terminus.

Protein Construction: A DNA sequence encoding the rat FCGR2B (Q63203-1) extracellular domain (Met 1-Pro 212) was expressed, fused with a polyhistidine tag at the C-terminus.

Fusion Tag: C-His

Species: Rat

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 97 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 21.9 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: FcγRIIB is a low affinity receptor that recognizes the Fc portion of IgG. The human CD32 group consists of FcγRIIA, FcγRIIB, and FcγRIIC proteins that share 94-99% sequence identity in their extracellular domains but differ substantially in their transmembrane and cytoplasmic domains. FcγRII protein is expressed on cells of both myeloid and lymphoid lineages as well as on cells of non-hematopoietic origin. FcγRIIB has an intrinsic cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and delivers an inhibitory signal upon ligand binding. Ligation of FcγRIIB on B cells down-regulates antibody production and in some circumstances may promote apoptosis. Co-ligation of FcγRIIB on dendritic cells inhibits maturation and blocks cell activation. FcγRIIB may also be a target for monoclonal antibody therapy for malignancies. FcγRIIB plays an important negative-regulating role through modulating the signals from activation receptors.

Research Area: N/A